Celecoxib has Preventive and Therapeutic Benefits against Nephrotoxicity Caused by Gentamicin in Mice
Drug Res (Stuttg) DOI: 10.1055/a-1785-4005It’s crucial to comprehend the impact of oxidative stress and
pro-inflammatory cytokines in the gentamicin-induced kidney injury mechanism.
Celecoxib was administered orally either before or after intraperitoneal therapy
with gentamicin in mice. The serum levels of creatinine (SCr), blood urea
nitrogen (BUN), IL-6, and TNF-α were measured by ELISA test, as well as
the levels of the kidney tissue malondialdehyde (MDA), and glutathione (GSH)
were also estimated spectrophotometrically. The renal expression of nuclear
factor-κB (NF-κB), interleukin-6 (IL-6), tumor necrosis
factor-α (TNF-α), and cyclooxygenase 2 (COX-2) mRNAs were
evaluated by qPCR. Histopathological evaluation and Immunohistochemical
examination of kidney NF-κB, IL-6, and COX-2 were also, performed.
Celecoxib successfully prevented gentamicin-induced kidney damage as indicated
by reducing blood BUN, SCr, and tissue MDA levels and increasing renal tissue
GSH levels as well as lowering the blood IL-6 and TNF-α in comparison to
mice received gentamicin. Furthermore, celecoxib has inhibited COX-2,
NF-κB, IL-6, and TNF-α expression in the renal tissue. It is
noteworthy that celecoxib therapy after gentamicin administration brought about
substantially the same results as celecoxib treatment before ge...
Source: Drug Research - Category: Drugs & Pharmacology Authors: Abd-Eldayem, Ahmed M. Dahpy, Marwa A. Badary, Dalia M. Alnasser, Sulaiman Mohammed Hareedy, Mohammad Salem Tags: Original Article Source Type: research